ECSP21093541A - Compuestos para el tratamiento de enfermedades y trastornos asociados con braf - Google Patents
Compuestos para el tratamiento de enfermedades y trastornos asociados con brafInfo
- Publication number
- ECSP21093541A ECSP21093541A ECSENADI202193541A ECDI202193541A ECSP21093541A EC SP21093541 A ECSP21093541 A EC SP21093541A EC SENADI202193541 A ECSENADI202193541 A EC SENADI202193541A EC DI202193541 A ECDI202193541 A EC DI202193541A EC SP21093541 A ECSP21093541 A EC SP21093541A
- Authority
- EC
- Ecuador
- Prior art keywords
- braf
- disorders
- compounds
- treatment
- associated diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se adjunta resumen de la invención
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868581P | 2019-06-28 | 2019-06-28 | |
| US202063021410P | 2020-05-07 | 2020-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21093541A true ECSP21093541A (es) | 2022-01-31 |
Family
ID=71465389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202193541A ECSP21093541A (es) | 2019-06-28 | 2021-12-28 | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11414404B2 (es) |
| EP (1) | EP3990437A1 (es) |
| JP (1) | JP7169469B2 (es) |
| KR (1) | KR102712548B1 (es) |
| CN (1) | CN114026073B (es) |
| AU (1) | AU2020302352B2 (es) |
| BR (1) | BR112021025102A2 (es) |
| CA (1) | CA3144859C (es) |
| CO (1) | CO2021017438A2 (es) |
| CR (1) | CR20210626A (es) |
| CU (1) | CU20210098A7 (es) |
| EC (1) | ECSP21093541A (es) |
| IL (1) | IL288214B2 (es) |
| MA (1) | MA56387A (es) |
| MX (1) | MX2021015903A (es) |
| PE (1) | PE20220341A1 (es) |
| PH (1) | PH12021552913A1 (es) |
| PY (1) | PY2030114A (es) |
| TW (1) | TWI817018B (es) |
| UY (1) | UY38767A (es) |
| WO (1) | WO2020261156A1 (es) |
| ZA (1) | ZA202201329B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PH12022551119A1 (en) * | 2019-12-10 | 2023-08-23 | Hoffmann La Roche | New methylquinazolinone derivatives |
| AU2020403082A1 (en) * | 2019-12-10 | 2022-05-12 | F. Hoffmann-La Roche Ag | New BRAF inhibitors as paradox breakers |
| IL297419B2 (en) * | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| TW202426436A (zh) | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| CN117940130A (zh) * | 2021-03-09 | 2024-04-26 | 基因泰克公司 | 用于脑癌治疗的贝伐拉非尼 |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| MX2023014059A (es) * | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| IL307964A (en) * | 2021-06-09 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Combined treatment for cancer |
| MX2023014629A (es) * | 2021-06-09 | 2024-01-30 | Hoffmann La Roche | Nuevas formas solidas de (3r)-n-[2-ciano-4-fluoro-3-(3-metil-4-oxo -quinazolin-6-il)oxi-fenil]-3-fluoro-pirrolidin-1-sulfonamida. |
| EP4426305A1 (en) * | 2021-11-04 | 2024-09-11 | F. Hoffmann-La Roche AG | Novel use of quinazolinone compound for the treatment of cancer |
| US20250011304A1 (en) * | 2021-12-08 | 2025-01-09 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024054591A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| EP4618994A1 (en) * | 2022-11-18 | 2025-09-24 | F. Hoffmann-La Roche AG | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| IL326137A (en) * | 2023-07-28 | 2026-03-01 | Cogent Biosciences Inc | PI3K inhibitors |
| TW202545530A (zh) * | 2024-01-17 | 2025-12-01 | 大陸商海思科醫藥集團股份有限公司 | 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用 |
| WO2025176139A1 (zh) * | 2024-02-20 | 2025-08-28 | 海思科医药集团股份有限公司 | 一种喹唑啉酮衍生物的晶型及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| CA2577275A1 (en) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| ES2405785T3 (es) | 2005-05-18 | 2013-06-03 | Array Biopharma Inc. | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos |
| CN101415689A (zh) | 2006-04-05 | 2009-04-22 | 阿斯利康(瑞典)有限公司 | 具有抗癌活性的经取代的喹唑啉 |
| JP2009532450A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ アクチボラグ | 化合物 |
| CN101421253A (zh) | 2006-04-18 | 2009-04-29 | 阿斯利康(瑞典)有限公司 | 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物 |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| AU2017204973A1 (en) | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| EP3684772B1 (en) | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| WO2019071351A1 (en) | 2017-10-12 | 2019-04-18 | Trillium Therapeutics Inc. | NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| CN113711012A (zh) | 2018-09-14 | 2021-11-26 | 联合利华知识产权控股有限公司 | 免洗型化妆品组合物保护皮肤免受污染的功效的评估 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
-
2020
- 2020-06-23 TW TW109121279A patent/TWI817018B/zh active
- 2020-06-24 CU CU2021000098A patent/CU20210098A7/es unknown
- 2020-06-24 EP EP20736786.3A patent/EP3990437A1/en not_active Withdrawn
- 2020-06-24 CN CN202080047143.1A patent/CN114026073B/zh active Active
- 2020-06-24 JP JP2021576777A patent/JP7169469B2/ja active Active
- 2020-06-24 PE PE2021002078A patent/PE20220341A1/es unknown
- 2020-06-24 CR CR20210626A patent/CR20210626A/es unknown
- 2020-06-24 WO PCT/IB2020/055992 patent/WO2020261156A1/en not_active Ceased
- 2020-06-24 IL IL288214A patent/IL288214B2/en unknown
- 2020-06-24 PH PH1/2021/552913A patent/PH12021552913A1/en unknown
- 2020-06-24 MX MX2021015903A patent/MX2021015903A/es unknown
- 2020-06-24 MA MA056387A patent/MA56387A/fr unknown
- 2020-06-24 AU AU2020302352A patent/AU2020302352B2/en active Active
- 2020-06-24 US US16/910,688 patent/US11414404B2/en active Active
- 2020-06-24 CA CA3144859A patent/CA3144859C/en active Active
- 2020-06-24 BR BR112021025102A patent/BR112021025102A2/pt unknown
- 2020-06-24 KR KR1020217042157A patent/KR102712548B1/ko active Active
- 2020-06-26 PY PY202002030114A patent/PY2030114A/es unknown
- 2020-06-26 UY UY0001038767A patent/UY38767A/es not_active Application Discontinuation
-
2021
- 2021-12-20 CO CONC2021/0017438A patent/CO2021017438A2/es unknown
- 2021-12-28 EC ECSENADI202193541A patent/ECSP21093541A/es unknown
-
2022
- 2022-01-27 ZA ZA2022/01329A patent/ZA202201329B/en unknown
- 2022-05-16 US US17/745,346 patent/US11634409B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11414404B2 (en) | 2022-08-16 |
| MA56387A (fr) | 2022-05-04 |
| CA3144859A1 (en) | 2020-12-30 |
| IL288214B2 (en) | 2025-03-01 |
| PY2030114A (es) | 2021-11-10 |
| UY38767A (es) | 2021-01-29 |
| MX2021015903A (es) | 2022-02-03 |
| JP7169469B2 (ja) | 2022-11-10 |
| BR112021025102A2 (pt) | 2022-01-25 |
| AU2020302352B2 (en) | 2023-03-23 |
| CR20210626A (es) | 2022-02-08 |
| IL288214A (en) | 2022-01-01 |
| CO2021017438A2 (es) | 2022-01-17 |
| CA3144859C (en) | 2023-09-12 |
| US20220289721A1 (en) | 2022-09-15 |
| IL288214B1 (en) | 2024-11-01 |
| CN114026073B (zh) | 2024-08-23 |
| WO2020261156A1 (en) | 2020-12-30 |
| CU20210098A7 (es) | 2022-06-06 |
| PH12021552913A1 (en) | 2022-04-04 |
| CN114026073A (zh) | 2022-02-08 |
| US11634409B2 (en) | 2023-04-25 |
| KR102712548B1 (ko) | 2024-09-30 |
| US20200407344A1 (en) | 2020-12-31 |
| AU2020302352A1 (en) | 2022-01-20 |
| TW202114996A (zh) | 2021-04-16 |
| TWI817018B (zh) | 2023-10-01 |
| JP2022539056A (ja) | 2022-09-07 |
| ZA202201329B (en) | 2023-09-27 |
| PE20220341A1 (es) | 2022-03-14 |
| KR20220011712A (ko) | 2022-01-28 |
| EP3990437A1 (en) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| IL280710A (en) | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| EA201790992A1 (ru) | Иммунорегуляторные агенты | |
| EP3784260A4 (en) | Compositions for the treatment of skin conditions | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| EP3807270C0 (en) | NOVEL HETEROCYCLYL HETEROARYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| HUE059638T2 (hu) | Ízületi gyulladásos betegségek kombinált kezelése | |
| EP3844156A4 (en) | TREATMENT OF HEPATIC DISORDERS | |
| CL2021002182A1 (es) | Formulación de anticuerpos terapéuticos | |
| EP3790563A4 (en) | Compositions for the treatment of skin conditions | |
| EP3959213C0 (en) | PYRIMIDINE-BASED JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| EP3883553A4 (en) | ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | |
| IL280664A (en) | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases | |
| IL310870A (en) | Quinazoline compounds for treatment of disease | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EP3927428C0 (en) | NORKETOTIFEN FOR THE TREATMENT OF RESPIRATORY DISORDERS | |
| MA54741A (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| EP3877383A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| IL282021A (en) | Compounds and compositions for treating conditions associated with apj receptor activity |